Literature DB >> 6462982

Immobilization hypercalcaemia with severe bone mineral loss and hypogonadism.

A G Need, H A Morris, M Horowitz, B E Nordin.   

Abstract

Moderate hypercalcaemia occurred in a 17-year-old male who was immobilized with abdominal and right hip sepsis for 9 months after a motor vehicle accident. The hypercalcaemia was due to bone resorption, with a urine hydroxyproline:creatinine ratio of 0.203 (normal less than 0.017) and a urine calcium loss of 22.9 mmol/24 hr, associated with impaired renal function. There was radiological evidence of severe bone demineralization in the pelvis over 42 weeks. Radiocalcium absorption, using 47Ca, was decreased (0.17, normal range 0.35-1.30), renal tubular maximum for calcium reabsorption was decreased (1.61 mmol/1 glomerular filtrate, normal range 1.8-2.2), the serum parathyroid hormone concentration was in the low normal range (3.2, 3.6 u/l, normal range 2-6) and the plasma 1,25-dihydroxy-vitamin D concentration was decreased despite a normal 25-hydroxy-vitamin D concentration, indicating suppression of the parathyroid, 1,25-dihydroxy-vitamin D axis. The patient was found to be hypogonadal at 41 weeks after admission and testosterone therapy was begun, with associated improvement in mobilization and a reduction of the hypercalcaemia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6462982      PMCID: PMC2417899          DOI: 10.1136/pgmj.60.704.415

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  18 in total

1.  Radiocalcium metabolism in disuse osteoporosis in man.

Authors:  R P HEANEY
Journal:  Am J Med       Date:  1962-08       Impact factor: 4.965

2.  Hypercalcemia in early traumatic quadriplegia.

Authors:  J Claus-Walker; R E Carter; R J Compos; W A Spencer
Journal:  J Chronic Dis       Date:  1975-02

3.  Longitudinal study of calcium and bone metabolism in paraplegic patients.

Authors:  P Bergmann; A Heilporn; A Schoutens; J Paternot; A Tricot
Journal:  Paraplegia       Date:  1977-08

4.  Parathyroid hormone and the hypercalcemia of immobilization.

Authors:  S Lerman; J M Canterbury; E Reiss
Journal:  J Clin Endocrinol Metab       Date:  1977-09       Impact factor: 5.958

5.  Immobilization hypercalcemia. Some new aspects of diagnosis and treatment.

Authors:  G D Lawrence; R G Loeffler; L G Martin; T B Connor
Journal:  J Bone Joint Surg Am       Date:  1973-01       Impact factor: 5.284

6.  The effect of calcitonin on immobilization osteopenia.

Authors:  R T Chiroff; J Jowsey
Journal:  J Bone Joint Surg Am       Date:  1970-09       Impact factor: 5.284

7.  Normalized androgen ratio: an index of free 17beta-hydroxysteroid concentration in serum.

Authors:  J M Gilliland; T C Smeaton; K Rowland
Journal:  Clin Chem       Date:  1978-09       Impact factor: 8.327

8.  Prospective trial of oestrogen and calcium in postmenopausal women.

Authors:  A Horsman; J C Gallagher; M Simpson; B E Nordin
Journal:  Br Med J       Date:  1977-09-24

9.  Bone metabolism in quadriplegia: dissociation between calciuria and hydroxyprolinuria.

Authors:  J Claus-Walker; W A Spencer; R E Carter; L S Halstead; R H Meier; R J Campos
Journal:  Arch Phys Med Rehabil       Date:  1975-08       Impact factor: 3.966

10.  Immobilization hypercalcemia crisis.

Authors:  J A Henke; N W Thompson; H Kaufer
Journal:  Arch Surg       Date:  1975-03
View more
  3 in total

Review 1.  Osteoporosis--a problem of bone formation?

Authors:  R Smith
Journal:  Postgrad Med J       Date:  1984-06       Impact factor: 2.401

2.  Aminohydroxypropylidene bisphosphonate (AHPrBP) treatment of severe immobilization hypercalcaemia in a young patient.

Authors:  N Varache; M Audran; P Clochon; A Lortholary; G Bouachour; P Alquier; M F Basle
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

3.  The gap between calculated and actual calcium substitution during citrate anticoagulation in an immobilised patient on renal replacement therapy reflects the extent of bone loss - a case report.

Authors:  Matthias Klingele; Sarah Seiler; Aaron Poppleton; Philip Lepper; Danilo Fliser; Roland Seidel
Journal:  BMC Nephrol       Date:  2014-10-04       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.